Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female and aged 18-80 years.~* Are willing to take a 6-SMT level evaluation test.~* Suffering from primary insomnia according to DSM-IV. criteria (307.42 primary insomnia, Appendix 24.3) .~* Sleep latency of at least 20 minutes.~* Have not been using benzodiazepines (BZD) and non-BZD hypnotics for the past 2 weeks or more.~* Have not been using psychotropic treatments for the past 3 months or more.~* Are stabilized on non-psychotropic treatments for more than 1 month.~* Are willing to sign a written informed consent to participate in the study.~Exclusion Criteria:~* Use of benzodiazepines or other hypnotics (including psychotropic treatments) during the study and preceding two weeks.~* Alcohol intake more than 30 g of pure alcohol per day and any intake after lunch-time.~* Pharmacological immunosuppression.~* Participation in a clinical trial with any investigational agent within two months prior to study enrollment.~* According to DSM IV, subjects belonging to the following groups are excluded: 780.59 (breathing related sleep disorder); 307.45 (circadian rhythm sleep disorder); 307.47 (dyssomnia not otherwise specified); 780.xx (sleep disorder due to general medical condition).~* Severe neurological, psychiatric disorders (especially psychosis, anxiety and depression) and alcoholism.~* Other serious diseases that could interfere with patient assessment.~* Pregnant or breast feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Circadin (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).